SEC Comment Letter 0000000000-24-012050 to CDT Equity Inc. (CDT)
CDT Equity Inc.
Date: Oct. 29, 2024 · CIK: 0001896212 · Accession: 0000000000-24-012050
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-282802
Letter
October 29, 2024 David Tapolczay Chief Executive Officer Conduit Pharmaceuticals Inc. 4995 Murphy Canyon Road, Suite 300 San Diego, CA 92134 Re:Conduit Pharmaceuticals Inc. Registration Statement on Form S-3 Filed October 24, 2024 File No. 333-282802 Dear David Tapolczay: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Todd Mason, Esq.
Show Raw Text
October 29, 2024
David Tapolczay
Chief Executive Officer
Conduit Pharmaceuticals Inc.
4995 Murphy Canyon Road, Suite 300
San Diego, CA 92134
Re:Conduit Pharmaceuticals Inc.
Registration Statement on Form S-3
Filed October 24, 2024
File No. 333-282802
Dear David Tapolczay:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Todd Mason, Esq.